Intuitive Surgical (ISRG) AI Stock Analysis

• Market Cap: $176.23B
• Dividend Yield: N/A
• Average Volume (3M): 1.99M
• Price to Earnings (P/E): 63.0
• Beta (1Y): 1.15
• Revenue Growth: 22.18%
• EPS Growth: 21.37%
• Country: US
• Employees: 15,638
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 2.53
• Shares Outstanding: 355,130,250
• 10 Day Avg. Volume: 1,447,247
• 30 Day Avg. Volume: 1,993,955
• PEG Ratio: 3.17
• Price to Book (P/B): 11.34
• Price to Sales (P/S): 20.08
• P/FCF Ratio: 81.16
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 17.23
• Enterprise Value/Gross Profit: 26.11
• Enterprise Value/Ebitda: 47.88
• 1Y Price Target: $647.56
• Price Target Upside: 30.49% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 19
• EPS Forecast (FY): 10.04
• Revenue Forecast (FY): $11.52B

• Rating: 75 Outperform
• Price Target: $566.00 ▲(14.06% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is driven primarily by excellent financial strength (strong growth, high margins, robust cash flow, and minimal leverage) and a favorable earnings outlook with continued procedure growth and platform adoption. These positives are moderated by a stretched valuation (high P/E), mixed-to-weak technical momentum versus key moving averages, and near-term margin headwinds highlighted in guidance (tariffs, mix/ASP pressure, and elevated operating expense growth).

Positive Factors

High recurring revenue mix

An 81% recurring revenue mix (consumables, instruments, service) creates durable, high‑visibility cash flows tied to procedure volume. This recurring stream supports margin sustainability, funds R&D and service capabilities, and reduces reliance on lumpy system placements over the medium term.

Very conservative balance sheet

Extremely low leverage and a sizeable equity base provide financial flexibility to invest in new platforms, absorb cyclical capital weakness, repurchase shares, and pursue M&A. This balance sheet strength materially reduces financial risk and supports durable capital deployment choices.

Expanding installed base and platform adoption

A growing installed base and rising utilization reinforce a self‑reinforcing revenue engine: more systems drive more consumable and service demand. Rapid adoption of new da Vinci 5, SP and Ion platforms broadens procedural reach and supports multi‑year organic growth.

Negative Factors

Gross margin headwinds

Tariff impacts and a higher mix of newer/lower‑margin systems (and related service costs) have compressed gross margins. Sustained tariff exposure and product mix shifts could limit margin expansion and constrain long‑term free cash flow conversion despite revenue growth.

Elevated operating expense trajectory

High OpEx growth guidance, one‑time large donations and ongoing hiring raise the baseline cost structure. If revenue leverage lags, sustained elevated operating spend will reduce operating margin upside and could slow the pace at which incremental revenue converts to free cash flow.

Intensifying China competitive/tender pressures

Local competitors and tender dynamics in China are creating structural pricing and placement pressure. Given China’s scale for future procedures, continued weak win rates or tender pressure could materially slow placement growth and reduce long‑term unit economics in a key market.

Intuitive Surgical Business Overview & Revenue Model

Company Description

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

How the Company Makes Money

Intuitive Surgical generates revenue primarily through the sale of its da Vinci Surgical Systems, as well as through recurring revenue streams from instruments and accessories and service agreements. The company sells its robotic systems to hospitals and surgical centers, which then purchase additional instruments and accessories for each procedure performed. These recurring sales contribute significantly to Intuitive Surgical's revenue. Additionally, the company offers service contracts to maintain and support the installed systems, providing another steady source of income. Key partnerships with healthcare providers and ongoing innovation in surgical technology further bolster Intuitive Surgical's earnings by expanding its market reach and enhancing its product offerings.

Intuitive Surgical Financial Statement Overview

Summary

High-quality fundamentals: strong multi-year revenue compounding to ~$10.06B (2025), consistently high gross margins (~66–69%) and strong net margins (~28% in 2025). Balance sheet is exceptionally conservative (debt-to-equity ~0.017) with improving ROE (~16% in 2025). Cash generation is robust (FCF ~$2.49B in 2025) with solid earnings-to-cash support, though FCF showed volatility in 2022–2023 and margins face modest pressure versus earlier peaks.

Income Statement

Revenue has compounded strongly from 2020 to 2025 (from ~$4.36B to ~$10.06B), with growth re-accelerating in 2024 and staying positive in 2025. Profitability is a clear strength: gross margin has remained consistently high (~66–69%) and net margin has held in the high-20% range recently (2025 ~28%). The main watch item is modest margin pressure versus earlier peaks (e.g., net margin below 2021 levels), suggesting profitability is strong but not fully expanding alongside revenue.

Balance Sheet

The balance sheet is exceptionally conservative, with very low leverage (debt-to-equity ~0.017 in 2025) and large, growing equity ($17.8B in 2025). Returns on equity are healthy and improving (roughly ~12% in 2022 to ~16% in 2025), signaling good capital efficiency without relying on debt. The primary weakness is limited—given the low leverage, the company is not using debt to amplify returns, but the trade-off is meaningfully lower financial risk.

Cash Flow

Cash generation is strong and improving, with operating cash flow rising to ~$3.03B in 2025 and free cash flow to ~$2.49B, supported by positive free-cash-flow growth in 2024 and 2025. Cash earnings quality is solid: operating cash flow exceeds net income (coverage ~1.51 in 2025), indicating profits are well supported by cash. The key weakness is historical volatility in free cash flow (notable declines in 2022–2023), though the recent rebound reduces concern.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.06B	8.35B	7.12B	6.22B	5.71B
Gross Profit	6.64B	5.63B	4.73B	4.20B	3.96B
EBITDA	3.62B	2.81B	2.17B	1.94B	2.13B
Net Income	2.86B	2.32B	1.80B	1.32B	1.70B
Balance Sheet
Total Assets	20.63B	18.84B	15.44B	12.97B	13.55B
Cash, Cash Equivalents and Short-Term Investments	5.93B	4.01B	5.22B	4.12B	4.23B
Total Debt	302.80M	146.00M	0.00	0.00	87.00M
Total Liabilities	2.69B	2.31B	2.04B	1.86B	1.60B
Stockholders Equity	17.82B	16.43B	13.31B	11.04B	11.95B
Cash Flow
Free Cash Flow	2.49B	1.30B	749.60M	958.40M	1.74B
Operating Cash Flow	3.03B	2.42B	1.81B	1.49B	2.09B
Investing Cash Flow	665.80M	-3.27B	-360.10M	1.37B	-2.46B
Financing Cash Flow	-2.36B	150.90M	-287.60M	-2.57B	43.00M

Intuitive Surgical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 496.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISRG, the sentiment is Negative. The current price of 496.25 is above the 20-day moving average (MA) of 493.19, below the 50-day MA of 530.25, and below the 200-day MA of 514.15, indicating a neutral trend. The MACD of -6.48 indicates Negative momentum. The RSI at 43.77 is Neutral, neither overbought nor oversold. The STOCH value of 65.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISRG.

Intuitive Surgical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	78 Outperform	$37.50B	25.33	25.68%	0.92%	9.36%	29.56%
ISRG	75 Outperform	$176.23B	63.01	16.67%	―	22.18%	21.37%
WST	72 Outperform	$18.10B	37.45	16.85%	0.32%	4.90%	-0.26%
BDX	68 Neutral	$50.27B	28.83	6.96%	2.13%	8.23%	-2.04%
HOLX	66 Neutral	$16.84B	31.31	10.86%	―	1.74%	-25.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	47 Neutral	$10.13B	-11.73	-13.75%	2.75%	-21.20%	-325.40%

Intuitive Surgical Corporate Events

Intuitive Surgical Expands Direct Robotic Operations in Southern Europe

On March 1, 2026, Intuitive completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates, as announced on March 2. The deal shifts distribution in Italy, Spain, Portugal, Malta, San Marino, and associated territories to a direct model, integrating these activities into Intuitive’s European commercial and marketing organization under Senior Vice President and General Manager Dirk Barten.

The acquisition expands Intuitive’s operational footprint in Southern Europe, where there were more than 470 installed da Vinci systems in Italy, Spain, and Portugal as of December 31, 2025, and where the Ion system was recently launched in Italy and Spain. Intuitive is also adding about 250 employees from the acquired businesses, a move expected to improve customer support, strengthen its competitive position in European robotic surgery, and potentially accelerate adoption of minimally invasive care across the region.

The most recent analyst rating on (ISRG) stock is a Hold with a $570.00 price target. To see the full list of analyst forecasts on Intuitive Surgical stock, see the ISRG Stock Forecast page.

Intuitive Surgical Restructures Digital and AI Leadership Role

Effective January 1, 2026, Intuitive Surgical announced that Brian E. Miller, Ph.D., will move from his current role as Chief Digital Officer to serve as Head of Digital and AI Strategy, shifting his responsibilities within the company’s leadership structure. In his new position, Miller will no longer report directly to the chief executive officer, signaling an internal reorganization of how Intuitive manages its digital and artificial intelligence initiatives, with potential implications for strategic oversight and the integration of these capabilities across the business.

The most recent analyst rating on (ISRG) stock is a Buy with a $650.00 price target. To see the full list of analyst forecasts on Intuitive Surgical stock, see the ISRG Stock Forecast page.